What is it about?
The main finding of our study is that the FDA-approved anti-inflammatory drug Celecoxib (also known as Celebrex), has beneficial effects on muscle function of mdx mice, a mouse model affected by muscular dystrophy. Celecoxib treatment also increased a protein called utrophin, which when highly expressed has been shown to improve dystrophic muscle.
Featured Image
Why is it important?
Our study focuses on finding a potential drug for the treatment of Duchenne Muscular Dystrophy (DMD). This fatal genetically-inherited neuromuscular is the most common form of muscular dystrophy that affects 1 in 3500 male live birth. Children living with this disease become wheelchair-bound by adolescence. Due to respiratory and cardiac complications death occurs in their second/third decade of life. Even though there are many promising approaches being developed to counteract the deleterious effects of DMD, there is still no cure today.
Perspectives
We hope that this article introduces new avenues for the treatment of Duchenne Muscular Dystrophy.
Christine Péladeau
University of Ottawa
Read the Original
This page is a summary of: Celecoxib treatment improves muscle function in mdx mice and increases utrophin A expression, The FASEB Journal, May 2018, Wiley,
DOI: 10.1096/fj.201800081r.
You can read the full text:
Contributors
The following have contributed to this page
